荆花胃康胶丸联合标准四联疗法对Hp相关性慢性胃炎患者的疗效研究

王瑞昕; 张声生; 周强

doi:10.3969/j.issn.1671-038X.2021.09.03

荆花胃康胶丸联合标准四联疗法对Hp相关性慢性胃炎患者的疗效研究

- 1. 北京中医药大学(北京, 100029);
- 2. 首都医科大学附属北京中医医院消化中心
基金项目:
北京市医管局培育计划（No：PZ2018010）

详细信息

通讯作者: 周强,E-mail:15101016416@126.com

中图分类号: R574.62

收稿日期: 2021-05-12

The research of curative effect of patients with Helicobacter pylori associated chronic gastritis treated by Jinghua Weikang Capsule combined with standard quadruple therapy

- 1. Beijing University of Chinese Medicine, Beijing, 100029, China;
- 2. Digestive Disease Center, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University

More Information

Corresponding author: ZHOU Qiang, E-mail: 15101016416@126.com

Received Date: 12 May 2021

摘要

摘要: 目的：评价荆花胃康胶丸联合标准四联疗法对于Hp相关性慢性胃炎患者（脾胃湿热证）的临床疗效。方法：选取77例西医诊断为Hp相关性慢性胃炎且经中医辨证为脾胃湿热证的患者为研究对象，随机分为对照组（38例）和实验组（39例）。对照组给予奥美拉唑钠肠溶片+枸橼酸铋钾胶囊+阿莫西林胶囊+克拉霉素片的标准四联疗法，实验组在此基础上给予荆花胃康胶丸口服，2组疗程均为14 d。在治疗结束后观察比较2组的Hp根除率、临床症状缓解程度和不良反应的发生情况。结果：2组患者在总Hp根除率方面差异无统计学意义（P>0.05），但亚组分析表明，实验组中痞满亚组的Hp根除率为100%，高于对照组的92%（P>0.05）。在临床症状缓解程度方面，实验组在治疗后的证候积分显著低于对照组（P<0.05），总有效率明显高于对照组（P<0.05）；且对于上腹胀、口臭、纳差及口苦4个单项症状的改善情况显著优于对照组（P<0.05）。结论：在根除Hp的常规四联疗法中加用荆花胃康胶丸对于Hp相关性慢性胃炎患者具有一定的增效作用，可以显著改善患者的临床症状，尤其是在上腹胀、纳差及口苦、口臭方面疗效明显。
- 荆花胃康胶丸 /
- 脾胃湿热证 /
- 痞满 /
- 四联疗法 /
- 幽门螺杆菌 /
- 慢性胃炎
Abstract: Objective: To evaluate the clinical effect of Jinghua Weikang Capsule combined with standard quadruple therapy on patients with chronic gastritis associated with Helicobacter pylori(syndrome of dampness-heat in spleen and stomach). Methods: Seventy-seven patients diagnosed as Helicobacter pylori associated chronic gastritis by Western medicine and diagnosed as dampness-heat syndrome of spleen and stomach by Traditional Chinese Medicine(TCM)syndrome differentiation were selected and randomly divided into control group(n=38) and experimental group(n=39). The control group was given omeprazole sodium enteric-coated tablets + bismuth potassium citrate capsules + amoxicillin capsules + clarithromycin tablets for 14 days, and the treatment group was given Jinghua Weikang Capsule combined with quadruplex therapy for 14 days. At the end of treatment, the eradication rate of helicobacter pylori, the remission degree of clinical symptoms and the occurrence of adverse reactions in the two groups were evaluated. Results: There was no significant difference in the eradication rate of Helicobacter pylori between the two groups(P>0.05), but the subgroup analysis showed that the eradication rate of Helicobacter pylori in Piman group was 100%, which was higher than that in the control group(92%,P>0.05). In terms of the degree of clinical symptom remission, the syndrome score of the experimental group was significantly lower than that of the control group(P<0.05), the total effective rate was significantly higher than that of control group(P<0.05). The improvement of the four single symptoms including upper abdominal distension, halitosis, poor tolerance and mouth bitterness was significantly better than the control group(P<0.05). Conclusion: Adding Jinghua Weikang Capsule to the conventional quadruple therapy to eradicate Helicobacter pylori has a synergism effect on patients with Helicobacter pylori associated chronic gastritis, and can significantly improve the clinical symptoms of patients, especially in the aspects of upper abdominal distension, poor tolerance, bitter mouth and halitosis.
- Jinghua Weikang Capsule /
- dampness-heat syndrome of spleen and stomach /
- Piman /
- quadruple therapy /
- Helicobacter pylori /
- chronic gastritis

HTML全文

参考文献(24)

[1]	Liu WZ, Zheng X, Shi Y, et al.Effect of Helicobacter pylori infection on gastric epithelial proliferation in progression from normal mucosa to gastriccarcinoma[J].World J Gastroenterol, 1998, 4(3):246-248.
[2]	Correa P, Haenszel W, Cuello C, et al.A model for gastric cancer epidemiology[J].Lancet, 1975, 2(7924):58-60.
[3]	郭继尧, 杜奕奇, 李兆申.根除幽门螺杆菌是降低胃癌发病率的必由之路[J].中国实用内科杂志, 2019, 39(6):506-510.
[4]	张建中.中国幽门螺杆菌治疗低根除率现状及应对策略[J].胃肠病学和肝病学杂志, 2017, 26(6):637-639.
[5]	江锋, 刘慧敏, 薛婧.中医药治疗幽门螺杆菌感染的现状分析与思考[J].中医杂志, 2021, 62(7):577-580, 598-598.
[6]	周强, 陶琳, 赵鲁卿, 等.中医药个体化辨证方案联合标准四联疗法根除幽门螺杆菌220例回顾性分析[J].北京中医药, 2018, 37(7):625-627.
[7]	杨佳卉, 梁雨, 罗培培, 等.荆花胃康联合三联或四联疗法与四联疗法对比治疗幽门螺杆菌相关慢性胃炎或消化性溃疡有效性和安全性的Meta分析[J].中国全科医学, 2019, 22(17):2091-2098.
[8]	史宗明, 叶晖, 张学智.中成药研究现状的文献可视化分析——以荆花胃康胶丸为例[J].中华中医药学刊, 2018, 36(3):586-590.
[9]	张声生.中成药临床应用指南——消化疾病分册[M].北京:中国中医药出版社, 2014.
[10]	林意珊.中西医结合新方案治疗幽门螺旋杆菌感染的临床观察[D].北京:北京中医药大学, 2017.
[11]	王瑞昕, 周强, 张声生, 等.祛湿清热法在幽门螺杆菌感染相关性胃病中的应用[J].现代中医临床, 2020, 27(1):49-53.
[12]	刘文忠, 谢勇, 陆红, 等.第五次全国幽门螺杆菌感染处理共识报告[J].胃肠病学, 2017, 22(6):346-360.
[13]	房静远, 杜奕奇, 刘文忠, 等.中国慢性胃炎共识意见(2017年, 上海)[J].胃肠病学, 2017, 22(11):670-687.
[14]	张声生, 唐旭东, 黄穗平, 等.慢性胃炎中医诊疗专家共识意见(2017)[J].中华中医药杂志, 2017, 32(7):3060-3064.
[15]	张声生, 刘凤斌, 侯政昆.脾胃病症状量化标准专家共识意见(2017)[J].中华中医药杂志, 2017, 32(8):3590-3596.
[16]	郑筱萸.中药新药临床研究指导原则[M].北京:中国医药科技出版社, 2002.
[17]	吴文珍.荆花胃康胶丸联合PPI三联疗法治疗Hp相关性慢性胃炎寒热错杂证的临床研究[D].南京:南京中医药大学, 2018.
[18]	阿依努尔·麦麦提热伊木, 高峰.幽门螺杆菌根除效果的影响因素分析[J].胃肠病学和肝病学杂志, 2020, 29(3):347-350.
[19]	姚国鹏, 李启祥, 段雪辉, 等.荆花胃康胶丸联用四联疗法补救治疗幽门螺杆菌感染的随机对照研究[J].现代消化及介入诊疗, 2020, 25(7):922-925.
[20]	姜欣, 刘丹, 韩林, 等.荆花胃康胶丸联合四联疗法治疗Hp阳性老年慢性胃炎的临床效果[J].中国医药导报, 2020, 17(18):155-158.
[21]	世界中医药学会联合会消化病专业委员会.痞满中医临床实践指南(2018)[J].中医杂志, 2019, 60(17):1520-1529.
[22]	王瑞昕, 刘玥芸.基于李东垣"脾胃盛衰论"探讨饮食不节所致脾胃不调的病机与调摄[J].中华中医药杂志, 2019, 34(7):2939-2941.
[23]	司鹏飞.基于口苦症状的流行病学调查及中西医身体观的比较研究[D].北京:北京中医药大学, 2017.
[24]	窦文欢.关于口臭与幽门螺杆菌感染相关性的一项Meta分析[D].苏州:苏州大学, 2016.